From Wikipedia, the free encyclopedia
Chemical compound
Erbulozole |
|
Other names | Erbuzole |
---|
|
CAS Number | |
---|
PubChem CID | |
---|
ChemSpider | |
---|
UNII | |
---|
|
Formula | C24H27N3O5S |
---|
Molar mass | 469.56 g·mol−1 |
---|
3D model (JSmol) | |
---|
CCOC(=O)NC1=CC=C(C=C1)SC[C@H]2CO[C@](O2)(CN3C=CN=C3)C4=CC=C(C=C4)OC
|
InChI=1S/C24H27N3O5S/c1-3-30-23(28)26-19-6-10-22(11-7-19)33-15-21-14-31-24(32-21,16-27-13-12-25-17-27)18-4-8-20(29-2)9-5-18/h4-13,17,21H,3,14-16H2,1-2H3,(H,26,28)/t21-,24+/m1/s1 Key:KLEPCGBEXOCIGS-QPPBQGQZSA-N
|
(verify) |
Erbulozole (R55104) is a congener of the microtubule inhibitor tubulozole. It is undergoing phase I clinical trials as a chemotherapeutic agent.[1]
- ^ Van Belle SJ, Distelmans W, Vandebroek J, Bruynseels J, Van Ginckel R, Storme GA (1993). "Phase I trial of erbulozole (R55104)". Anticancer Research. 13 (6B): 2389–91. PMID 8135472.
- Distelmans W, VanGinckel P, Heeres J, Van der Veken LJ (1991). "Erbulozole. Antineoplastic, Microtubule inhibitor". Drugs Future. 16 (6): 577.
|
---|
CI monoclonal antibodies ("-mab") | |
---|
Tyrosine kinase inhibitors ("-nib") | Receptor tyrosine kinase |
- RET inhibitors: Entrectinib (ALK, ROS1, NTRK), Futibatinib (FGFR2), Infigratinib, Larotrectinib (NTRK), Pemigatinib (FGFR), Pralsetinib, Repotrectinib (ROS1, TRK, ALK), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
|
---|
Non-receptor | |
---|
|
---|
Other | |
---|